Second pivotal phase 3 study Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH).

Trial Profile

Second pivotal phase 3 study Fedovapagon in the Treatment of Nocturia in Men With Benign Prostatic Hyperplasia (BPH).

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Fedovapagon (Primary)
  • Indications Nocturia
  • Focus Registrational; Therapeutic Use
  • Sponsors Vantia Therapeutics
  • Most Recent Events

    • 05 Oct 2017 New trial record
    • 03 Oct 2017 According to a Vantia Therapeutics media release, Data from this trial will be used to support regulatory filings for marketing approval in the US and Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top